26.1 - Precision Biologics, Refractory Phenotypes, and Cardiovascular Safety

In this episode, we dive into the latest breakthrough research from early 2026 and late 2025, focusing on shifting paradigms in the treatment of Lupus and Rheumatoid Arthritis. We explore the rapid effects of Litifilimab, a novel approach to preventing Cardiac Neonatal Lupus, the hidden "NIRRA" phenotype in RA, and the crucial role of statins in JAK inhibitor safety. Litifilimab in Lupus (LILAC Trial): A deep dive into how targeting BDCA2 on pDCs leads to rapid and sustained reductions in Type I Interferon gene expression and cytokines in SLE and CLE patients. Link: ⁠https://doi.org/10.1002/art.43271⁠ Preventing Cardiac Neonatal Lupus: A proof-of-concept study on using Rozanolixizumab (an FcRn blocker) during pregnancy to inhibit the transplacental transfer of pathogenic anti-SSA/Ro antibodies. Link: ⁠https://doi.org/10.1016/j.ard.2025.09... Refractory RA Phenotypes (PIRRA vs. NIRRA): Why some RA patients fail multiple biologics despite low inflammation. We discuss the use of synovial biopsies to distinguish between inflammatory and pauci-immune/fibroid "noninflammatory" refractory RA. Link: ⁠https://doi.org/10.1016/j.ard.2025.07... Statins and Tofacitinib Safety (ORAL Surveillance): New post-hoc analysis showing that proper statin use may mitigate the increased risk of MACE observed with tofacitinib in high-risk ASCVD patients. Link: ⁠https://doi.org/10.1016/j.ard.2025.08... For visual learners, we provide complete infographics and one-page summaries of every article discussed in this episode. Follow our WhatsApp Channel for the visual guides and infographics: ⁠⁠https://whatsapp.com/channel/0029Vb6P...